Ocular Therapeutix has submitted a supplemental new drug application for Dextenza as a treatment for ocular itching associated with allergic conjunctivitis, according to a press release.
The dexamethasone ophthalmic insert 0.4 mg is already approved for intracanalicular use for treatment of postoperative ocular pain and inflammation.
A pooled analysis of four vehicle-controlled clinical trials including 323 subjects with ocular allergies and positive skin test reaction to perennial and seasonal allergens demonstrated lower ocular mean itching scores for Dextenza relative to placebo vehicle with
Uncategorized